<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00616460</url>
  </required_header>
  <id_info>
    <org_study_id>0124-07-EMC</org_study_id>
    <nct_id>NCT00616460</nct_id>
  </id_info>
  <brief_title>ACRIPAB- Trial: Anti Coagulation Regimen In High Risk PAtients for Bleeding</brief_title>
  <acronym>ACRIPAB</acronym>
  <sponsors>
    <lead_sponsor>
      <agency>HaEmek Medical Center, Israel</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>HaEmek Medical Center, Israel</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      To determine the safety/efficacy of Bivallirudin Vs unfractionated heparin (UFH) on top of
      dual antiplatelet therapy in patients with high tendency for bleeding during urgent and
      elective PCI.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>February 2008</start_date>
  <completion_date type="Actual">October 2011</completion_date>
  <primary_completion_date type="Actual">October 2011</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double (Participant, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>End points: Primary :Major &amp; minor bleeding Port of entry related complications</measure>
    <time_frame>30 days</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>End points: Secondary: 30 days MACE</measure>
    <time_frame>30 days</time_frame>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">100</enrollment>
  <condition>Hematologic Diseases</condition>
  <arm_group>
    <arm_group_label>Bivalirudin</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Bivalirudin</intervention_name>
    <description>Bivalirudin: loading dose 0.75mg/kg bolus During procedure: 1.75mg/kg/hour. UFH: loading dose 60 Units /kg During procedure: keeping ACT &lt; 250</description>
    <arm_group_label>Bivalirudin</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

        Inclusion criteria (any of the following):

          -  â‰¥75 years

          -  Creatinin clearance rate &lt; 60 ml per minute

          -  Anemia (Hb 9-11 mg%)

          -  Hypertension: BP &gt; 180/95 mmHg but less than 210/110 m Hg

          -  Diabetic Pts

          -  Steroid treated Pts

          -  Recent (within 6 weeks) non major surgery

          -  Pts with hematological disorders associated with tendency for bleeding like
             Thrombocytopenia (platelets 50000-150000) included TTP;

        Exclusion Criteria:

        Exclusion criteria:

          -  Age &lt; 18 year

          -  Acute STEMI (Primary PCI)*

          -  Rescue angioplasty &lt;12h after lytic therapy*

          -  Active bleeding

          -  S.C LMWH &lt; 8 hours or UFH &lt; 4 hours before PCI

          -  Using IIb /IIIa as an upstream therapy before PCI

          -  PCI which will be involved with obligatory IIb /IIIa therapy:

        (thrombotic complication, occlusive dissection)

          -  INR&gt;1.5 on day of cathetrization

          -  Bolus of 600mg of Clopidogrel before PCI

          -  Current pregnancy or women in reproductive age without contraceptives

          -  Hypersensitivity to heparin or bivalirudin or its components *(possible using
             IIB/IIIA)
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Yoav Turgeman, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Heart Institute HaEmek medical center</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Heart Institute haEmek Medical Center</name>
      <address>
        <city>Afula</city>
        <zip>18101</zip>
        <country>Israel</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Israel</country>
  </location_countries>
  <verification_date>June 2015</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>February 5, 2008</study_first_submitted>
  <study_first_submitted_qc>February 14, 2008</study_first_submitted_qc>
  <study_first_posted type="Estimate">February 15, 2008</study_first_posted>
  <last_update_submitted>June 11, 2015</last_update_submitted>
  <last_update_submitted_qc>June 11, 2015</last_update_submitted_qc>
  <last_update_posted type="Estimate">June 12, 2015</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>HaEmek Medical Center, Israel</investigator_affiliation>
    <investigator_full_name>Turgeman Yoav</investigator_full_name>
    <investigator_title>Chief of Cardiology Department</investigator_title>
  </responsible_party>
  <keyword>safety</keyword>
  <keyword>efficacy</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Hematologic Diseases</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Bivalirudin</mesh_term>
    <mesh_term>Hirudins</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

